Glutaminase (GLS) inhibitors, such as CB-839, have demonstrated significant anti-tumor effects in preclinical models by inhibiting glutamine metabolism and disrupting the carbon and nitrogen supply essential for tumor cell survival (51). Here, GLS is linked to neoplasm.